TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Sponsor: Replimune, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,263,800

Rescue Site Savings

+$1,478,400

Unlock Full NCT05733598 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05733598 Rescue Dossier →